Information Provided By: 
Fly News Breaks for April 6, 2016
EGRX
Apr 6, 2016 | 07:18 EDT
After spending time with management, Piper Jaffray analyst David Amsellem sees "significantly more upside potential than downside risk" in shares of Eagle Pharmaceuticals just from the potential for Ryanodex in exertional heat stroke alone. Amsellem adds that while Bendeka generic filers create near-term risk, he remains confident in a favorable litigation outcome. The analyst reiterates an Overweight rating on Eagle with a $98 price target. The stock closed yesterday down 78c to $39.16.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
